查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1676874

兒童肺炎鏈球菌治療市場按產品類型、年齡層、疾病類型、給藥方式、治療用途和最終用戶分類 - 2025 年至 2030 年全球預測

Pediatrics Pneumococcal Therapeutics Market by Product, Age Group, Disease Type, Mode of Administration, Therapeutic Applications, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

兒童肺炎鏈球菌藥物市場預計在 2024 年達到 121.8 億美元，2025 年達到 131.5 億美元，到 2030 年將達到 194.9 億美元，複合年成長率為 8.14%。

主要市場統計數據
基準年 2024 年 121.8億美元
預計 2025 年 131.5億美元
預測年份 2030 194.9億美元
複合年成長率（%） 8.14％

近年來，隨著新的研究、先進的技術和對病原體動態的更深入的了解，兒童肺炎球菌治療發生了重大變革時期。新治療方法的開發不僅改善了臨床結果，而且促進了加強兒童呼吸道感染疾病的預防策略。本介紹全面概況了當前的治療狀況，並概述了技術創新和資料驅動的見解在治療兒童肺炎鏈球菌感染方面發揮的關鍵作用。

儘管長期以來一直推行疫苗接種和治療方法，肺炎鏈球菌感染仍然是全世界兒童發病和死亡的主要原因之一。由於這種感染疾病負擔繼續挑戰全球醫療保健系統，因此，重新定義一種將預防措施和先進的治療性介入結合的方法至關重要。臨床醫生、研究人員和醫療保健政策制定者都致力於利用尖端科學和市場情報來制定有效、長期永續的解決方案。

由於兒科病原體的內在複雜性以及肺炎鏈球菌感染的多種臨床表現，需要調整策略。本書以實證實踐為重點，旨在揭示改變治療格局的趨勢、創新和策略市場變化，最終有助於改善患者的治療效果並提高醫療管理的效率。該領域專注於切實可行的見解，從傳統的治療模式轉變為以患者為中心的綜合方法。

了解目前的研究和治療狀況可以幫助相關人員更好地認知到對抗兒童肺炎鏈球菌感染所做的多方面努力。隨後的討論包括對新興趨勢、競爭考察、區域動態和競爭環境的全面審查，所有這些都預示著兒科醫療保健的美好未來。

兒童肺炎鏈球菌藥物的變革

近年來，由於生物技術的進步、不斷發展的法律規範和新的臨床指南，兒童肺炎球菌治療方法發生了重大變化。治療市場目前正在經歷模式轉移，重點從被動治療感染疾病轉向透過精準醫療和個人化免疫策略進行主動管理。

藥物治療的進步帶來了超越傳統抗生素治療的創新浪潮。基於新機制的治療方法，特別是識別和針對特定細菌毒力因子的治療方法，已成為有希望的選擇。同時，疫苗研發已成為全球對抗肺炎鏈球菌感染的核心。疫苗正變得越來越複雜，利用結合物和多醣製劑來擴大為兒童提供的免疫保護頻譜。這種對治療和預防的雙重關注使我們能夠更好地解決各種臨床表現和病原體菌株所帶來的複雜問題。

目前最大的變化之一涉及個人化醫療的整合。透過基因分析和生物標記識別，治療可以更加個人化，減少抗生素抗藥性和副作用的可能性，同時提高疫苗接種計劃的有效性。向個人化治療策略的轉變不僅滿足了個別患者的獨特需求，而且符合旨在減輕感染疾病負擔的全球醫療政策。

數位健康和​​高級分析進一步改變了臨床決策。綜合健康資訊系統使醫療保健專業人員能夠即時監測患者治療結果，快速調整治療通訊協定，並更準確地追蹤流行病學趨勢。這些技術對改善治療流程和確保兒科患者得到最適當和及時的護理做出了巨大貢獻。

摘要，兒童肺炎球菌治療的變革性轉變的特點是創新藥物開發、先進疫苗技術和數位健康解決方案的融合。總的來說，這些要素賦予了醫療保健提供者權力，有助於重組主動護理格局，優先考慮患者安全、提高療效，並為患有肺炎鏈球菌感染的兒童提供適應性治療方法。

深入了解兒童肺炎鏈球菌藥物的關鍵領域

透過詳細的細分分析可以準確了解兒童肺炎球菌治療市場。可以從多個角度對這個市場進行分析，例如治療產品的性質、年齡層、疾病類型、給藥方式、在侵入性和非侵入性條件下的應用以及最終用戶設定。

基於產品的細分區分藥品和疫苗。在醫藥領域，傳統藥物療法仍然是對抗感染疾病的關鍵，而疫苗領域則不斷發展，並深度分類為結合疫苗和多醣體疫苗。每種疫苗都有不同的免疫抗原性原性，與傳統疫苗相比，結合疫苗在幼兒身上能引發更強的免疫反應。

若以年齡層來考慮市場，嬰幼兒是主要目標。這種區分至關重要，因為年輕族群的免疫成熟度和感染疾病易感性差異很大，需要製定個人化的治療方法。

考慮到疾病類型，研究了細菌性肺炎、黴漿菌肺炎和病毒性肺炎的治療市場。每種臨床狀況都需要其獨特的治療途徑。細菌性肺炎通常進展更為嚴重，需要積極及時的干涉，而黴漿菌和病毒性肺炎可能需要不同的治療策略，包括支持性治療和特定的抗病毒方案。

另一個重點是管理方法。有幾種治療選擇，包括肌肉注射、鼻腔注射、靜脈注射和口服。每種方法都有其優點和局限性，會影響藥物輸送速度和患者的依從性。同時，口服給藥方便，支持門診病人遵守治療方案。

根據治療應用，市場進一步細分為侵入性肺炎鏈球菌感染治療和非侵入性肺炎鏈球菌感染治療。前者包括菌血症和腦膜炎等嚴重，對於這些疾病，迅速而有力的干涉至關重要。另一方面，中耳炎和鼻竇炎等非侵入性肺炎球菌疾病雖然不太嚴重，但需要精心治療以防止併發症並改善生活品質。

實施治療的環境也提供了一層分割。最終用戶範圍從診所、醫院到居家醫療，反映了提供兒科護理的多種環境以及影響獲得護理機會的各種經濟促進因素。

綜合起來，這些細分的見解揭示了一個多面向且充滿活力的市場。了解這些方面將使相關人員能夠針對兒科族群的特定需求，並確保治療通訊協定不僅有效，而且還能適應臨床和居家照護的現實環境。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 提高家長和醫護人員對肺炎鏈球菌感染的認知
      • 合併疫苗使用增加導致兒童肺炎鏈球菌藥物增加
      • 政府推動疫苗接種和預防性保健的措施和政策
    • 限制因素
      • 高昂的研發成本限制了新進者
    • 機會
      • 開發適合年齡的配方，以適應不同年齡的兒童
      • 投資遠端醫療技術以擴大覆蓋範圍並改善患者治療效果
    • 任務
      • 回應日益成長的倫理擔憂和對兒童藥物試驗透明度的要求
  • 市場區隔分析
    • 產品：已證實對嬰兒有效，從而推動結合疫苗的普及
    • 治療應用：擴大兒童肺炎鏈球菌藥物在侵襲性肺炎鏈球菌疾病的應用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 兒童肺炎鏈球菌藥物市場（依產品）

  • 藥品
  • 疫苗
    • 結合疫苗
    • 多醣體疫苗

7. 兒童肺炎鏈球菌藥物市場（依年齡層）

  • 嬰兒
  • 嬰兒

8. 兒童肺炎鏈球菌藥物市場（依疾病類型）

  • 細菌性肺炎
  • 肺炎黴漿菌
  • 病毒性肺炎

9. 兒童肺炎鏈球菌藥物市場（依給藥方式）

  • 肌肉注射
  • 鼻腔內
  • 靜脈
  • 口服

10. 兒童肺炎鏈球菌治療市場-治療應用

  • 侵襲性肺炎鏈球菌感染
    • 菌血症
    • 腦膜炎
  • 非侵襲性肺炎鏈球菌疾病
    • 中耳炎
    • 鼻竇炎

第 11 章兒童肺炎鏈球菌藥物市場（按最終用戶）

  • 診所
  • 家庭護理設置
  • 醫院

12. 美國兒童肺炎鏈球菌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區兒童肺炎鏈球菌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14. 歐洲、中東和非洲兒童肺炎鏈球菌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Bharat Biotech International Limited
  • Biocon Limited
  • BioNTech SE
  • CanSino Biologics Inc.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hoffmann-La Roche AG
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila
Product Code: MRR-E336711C9EF2

The Pediatrics Pneumococcal Therapeutics Market was valued at USD 12.18 billion in 2024 and is projected to grow to USD 13.15 billion in 2025, with a CAGR of 8.14%, reaching USD 19.49 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 12.18 billion
Estimated Year [2025] USD 13.15 billion
Forecast Year [2030] USD 19.49 billion
CAGR (%) 8.14%

In recent years, pediatric pneumococcal therapeutics have undergone a significant transformation, driven by emerging research, advanced technologies, and a deeper understanding of pathogen dynamics. The development of novel therapeutic approaches has not only improved clinical outcomes but has also fostered enhanced preventive strategies against respiratory infections in children. This introduction provides a comprehensive overview of the current therapeutic environment, outlining the pivotal role of innovation and data-driven insights in addressing pneumococcal diseases in the pediatric population.

Pneumococcal infections remain one of the leading causes of childhood morbidity and mortality worldwide, despite longstanding vaccination and treatment regimens. As the burden of these infections continues to challenge healthcare systems globally, a redefined approach that integrates both preventive measures and advanced therapeutic interventions has become indispensable. Clinicians, researchers, and healthcare policymakers are all converging on the need to harness cutting-edge science and market intelligence to tailor solutions that are both effective and sustainable over time.

The necessity to adapt strategies arises from the inherent complexity of pediatric pathogens and the diverse clinical manifestations of pneumococcal diseases. With a focus on evidence-based practice, this narrative seeks to illuminate the trends, innovations, and strategic market shifts that are reshaping the therapeutic landscape, ultimately contributing to improved patient outcomes and more efficient healthcare management. Emphasis is placed on actionable insights as the sector pivots from traditional treatment paradigms in favor of integrated, patient-centric approaches.

By understanding the current state of research and therapy, stakeholders can better appreciate the multi-dimensional efforts underway to combat pneumococcal diseases in children. The discussions that follow comprise a thorough exploration of emerging trends, segmentation insights, regional dynamics, and the competitive environment, all of which signal a promising future for pediatric healthcare.

Transformative Shifts in Pediatric Pneumococcal Therapeutics

Recent years have witnessed transformative shifts in the approaches to pediatric pneumococcal therapeutics, driven by advancements in biotechnology, evolving regulatory frameworks, and novel clinical guidelines. The therapeutic market is now experiencing a paradigm shift as emphasis moves from reactive treatment of infections towards proactive management with precision medicines and tailored immunization strategies.

The evolution of drug therapies has brought a wave of innovation that extends beyond traditional antibiotic treatments. Newer, mechanism-based therapies, particularly those that identify and target specific bacterial virulence factors, have emerged as promising alternatives. In parallel, vaccine development has taken center stage in the global fight against pneumococcal diseases. Vaccines have become increasingly sophisticated, leveraging conjugate and polysaccharide formulations to broaden the spectrum of immune protection offered to children. This dual focus on both therapeutics and preventive measures ensures a robust response to the complexities presented by varying clinical presentations and pathogen strains.

One of the most significant changes in the landscape relates to the integration of personalized medicine. Through genetic profiling and biomarker identification, treatments are becoming more customized, reducing the likelihood of antibiotic resistance and adverse reactions, while enhancing the effectiveness of immunization schedules. The shift towards personalized treatment strategies not only caters to the unique needs of individual patients but also aligns with global healthcare policies aimed at reducing the burden of infectious diseases.

Digital health and advanced analytics have further transformed decision-making within clinical settings. Integrated health information systems allow practitioners to monitor patient outcomes in real time, adjust therapeutic protocols promptly, and track epidemiological trends more accurately. These technologies contribute significantly to refining treatment algorithms and ensuring that pediatric patients receive the most appropriate and timely care.

In summary, the transformative shifts in pediatric pneumococcal therapeutics are characterized by the convergence of innovative drug development, advanced vaccine technologies, and digital health solutions. These elements collectively empower healthcare providers, contributing to a reimagined and proactive therapeutic landscape that prioritizes patient safety, improved efficacy, and adaptive treatment modalities for children suffering from pneumococcal diseases.

Key Segmentation Insights in Pediatric Pneumococcal Therapeutics

A nuanced understanding of the pediatric pneumococcal therapeutics market is best achieved through detailed segmentation analysis. The market can be analyzed from several perspectives including the nature of the therapeutic product, age cohort, type of disease, mode of administration, applications in invasive and non-invasive conditions, and the end-user setting.

The product-based segmentation distinguishes between pharmaceuticals and vaccines. In the pharmaceutical segment, traditional drug therapies remain integral to immediate infection control, while the vaccine segment continues to evolve with its deeper categorization into conjugate vaccines and polysaccharide vaccines. These vaccine types offer distinct immunogenic profiles, with conjugate vaccines providing a more robust immune response in young children compared to traditional formulations.

When examining the market through the lens of age groups, the primary segments under review include infants and toddlers. This distinction is essential, as immunological maturity and the susceptibility to infections vary significantly between these young cohorts, thereby informing tailored therapeutic regimens.

Considering the disease typology, the therapeutic market is studied with reference to bacterial pneumonia, mycoplasma pneumonia, and viral pneumonia. Each of these clinical presentations demands a unique treatment pathway. Bacterial pneumonia, often more severe in its progression, necessitates aggressive and timely intervention, whereas mycoplasma and viral pneumonia may require alternative management strategies including supportive care and specific antiviral regimens.

Another crucial dimension is the mode of administration. Treatment modalities encompass several options including intramuscular, intranasal, intravenous, and oral routes. Each of these methods presents its own set of benefits and limitations, influencing both the speed of drug delivery and patient compliance. Intramuscular injections often deliver rapid systemic effects, while the ease of oral administration supports adherence to treatment protocols in outpatient settings.

Therapeutic applications further segment the market into treatments for invasive pneumococcal diseases and non-invasive pneumococcal diseases. The former includes serious conditions like bacteremia and meningitis, where swift and potent intervention is critical. Conversely, non-invasive conditions such as otitis media and sinusitis, though less severe, still require careful management to prevent complications and promote quality of life.

The setting in which treatment is rendered also provides a layer of segmentation. End-users range from clinics and hospitals to homecare settings, reflecting the varied contexts in which pediatric care is administered and the diverse economic dynamics influencing therapeutic access.

Collectively, these segmented insights underscore a market that is multifaceted and dynamic. Understanding these dimensions allows stakeholders to target specific needs within the pediatric population, ensuring that therapeutic protocols are not only effective but also tailored to meet the practical realities of both clinical and homecare environments.

Based on Product, market is studied across Drug and Vaccine. The Vaccine is further studied across Conjugate Vaccine and Polysaccharide Vaccine.

Based on Age Group, market is studied across Infants and Toddlers.

Based on Disease Type, market is studied across Bacterial Pneumonia, Mycoplasma Pneumonia, and Viral Pneumonia.

Based on Mode of Administration, market is studied across Intramuscular, Intranasal, Intravenous, and Oral.

Based on Therapeutic Applications, market is studied across Invasive Pneumococcal Diseases and Non-Invasive Pneumococcal Diseases. The Invasive Pneumococcal Diseases is further studied across Bacteremia and Meningitis. The Non-Invasive Pneumococcal Diseases is further studied across Otitis Media and Sinusitis.

Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.

Key Regional Insights on Global Pediatric Pneumococcal Therapeutics Trends

Analyzing regional trends in pediatric pneumococcal therapeutics reveals unique market dynamics and growth opportunities that are shaped by local healthcare infrastructures, regulatory environments, and epidemiological profiles. The market's global evolution can be distilled into insights pertinent to regions such as the Americas, Europe including the Middle East and Africa, and Asia-Pacific.

In the Americas, robust healthcare systems and substantial investments in vaccine research and pharmaceutical innovations have driven significant advancements. Countries with well-established immunization programs have seen marked reductions in pneumococcal disease prevalence, which further spurs demand for novel therapeutic solutions that optimize treatment protocols and reduce the reliance on antibiotics. The increased focus on surveillance and early intervention in these regions is also shaping market strategies and fostering collaborations aimed at expanding pediatric care.

The region encompassing Europe, the Middle East, and Africa exhibits a complex tapestry of challenges and opportunities. European countries typically benefit from high technological readiness and stringent regulatory oversight, which collectively enhance the quality and safety of new therapeutics. In contrast, parts of the Middle East and Africa are experiencing rapid demographic changes and evolving healthcare frameworks, which have created a fertile ground for introducing innovative and adaptable treatment policies. Investments in infrastructure and cross-border healthcare initiatives are broadening access to both vaccines and drug therapies, thereby driving market growth even in resource-limited settings.

Across the Asia-Pacific region, the dynamics of pediatric healthcare are influenced by a combination of high population density, varying levels of economic development, and diverse public health policies. Asia-Pacific markets have witnessed increased domestic production of vaccines and a surge in research collaborations that aim to tailor treatments to local disease profiles. In addition to the rapid urbanization and rising disposable incomes in many countries within this region, there is an ever-growing emphasis on the integration of digital healthcare solutions that facilitate timely diagnosis and efficient treatment delivery.

These regional insights highlight the importance of a localized approach when designing and deploying pediatric pneumococcal therapeutics. Strategic market entrants and incumbents alike must adapt their offerings to the specific regulatory and economic contours of each region, ensuring that innovations developed in one part of the world can be successfully transposed to meet the needs of diverse patient populations globally.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Key Companies in the Therapeutics Market

The competitive environment within pediatric pneumococcal therapeutics is populated by a diverse array of companies, each contributing uniquely to the market dynamics. A thorough competitive analysis reveals that the landscape is characterized by both long-established pharmaceutical giants and innovative biotechnological firms. Prominent companies driving this sector include AbbVie Inc., Astellas Pharma Inc., and AstraZeneca PLC, whose extensive research and development portfolios have enabled them to stay at the forefront of therapeutic innovation.

In addition, companies such as Aurobindo Pharma Limited and Baxter International Inc. have demonstrated strong capabilities in scaling production while ensuring the availability of high-quality drug interventions. Bharat Biotech International Limited and Biocon Limited have also made significant contributions, particularly through their breakthroughs in vaccine development, which have enabled more effective preventative measures against pneumococcal infections.

Biotech disruptors like BioNTech SE and CanSino Biologics Inc. are emerging with novel approaches and agile development cycles, further intensifying competition in the vaccine segment. The presence of well-established entities like CSL Limited, along with firms such as Daiichi Sankyo Company, Limited, and Dr. Reddy's Laboratories Ltd., adds to the market's strategic depth.

Notable players such as Eli Lilly and Company, GlaxoSmithKline plc, and Glenmark Pharmaceuticals bring decades-long expertise in drug formulations and patient care innovations. The landscape is further enriched by global powerhouses like Hoffmann-La Roche AG, Johnson & Johnson, and Lupin Limited, whose focus on ensuring safety and efficacy continues to shape therapeutic trends.

Additional major contributors include Merck & Co., Inc., Moderna, Inc., Novartis AG, and Novavax, Inc., each investing heavily in research that expands the scientific understanding of immune responses in children. Entities like Panacea Biotec Ltd., Pfizer Inc., and Sanofi S.A. have maintained a robust presence in both the drug and vaccine sectors, supported by extensive clinical networks and advanced manufacturing capabilities.

The competitive scene is rounded out by influential firms such as Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila, all of which continue to push the envelope in therapeutic innovations.

Overall, the industry is marked by high levels of competition, with each company leveraging its unique strengths to cater to a broad spectrum of pediatric healthcare needs. Their combined efforts are not only enhancing the quality of care but are also fostering an environment ripe for further scientific exploration and market expansion.

The report delves into recent significant developments in the Pediatrics Pneumococcal Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Bharat Biotech International Limited, Biocon Limited, BioNTech SE, CanSino Biologics Inc., CSL Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Hoffmann-La Roche AG, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Moderna, Inc., Novartis AG, Novavax, Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila. Actionable Recommendations for Industry Leaders in Pediatric Therapeutics

Industry leaders looking to capitalize on the evolving landscape of pediatric pneumococcal therapeutics must adopt a range of strategic actions to secure a competitive edge and ensure sustainable growth. One of the primary recommendations is to invest robustly in research and development initiatives that target both drug and vaccine innovations. Continuous investment in R&D not only accelerates the discovery of novel therapeutic agents but also enhances the refinement of existing products to address emerging resistance patterns and changing epidemiological trends.

Another key recommendation is to foster strategic partnerships that span across academia, biotechnology firms, and clinical institutions. Collaboration facilitates the pooling of expertise, resources, and technological innovation, thereby expediting the development cycle for new products. In a market where time-to-market can be a critical factor, integrated partnerships enable quicker adaptation to regulatory changes and swift dissemination of breakthroughs.

Industry leaders should also focus on enhancing their digital infrastructure. The integration of data analytics, real-time patient monitoring, and advanced diagnostic tools can not only fine-tune treatment protocols but also drive personalized medicine initiatives that cater to the distinctive needs of infants and toddlers. Embracing digital technologies helps ensure that therapeutic solutions remain patient-centric, efficient, and adaptive to real-world challenges.

Furthermore, expanding market outreach in emerging economies presents an untapped opportunity. A geographic focus on regions with evolving healthcare systems - where demand is rising due to increasing awareness and enhanced healthcare funding - can lead to substantial market penetration and revenue growth. By tailoring product portfolios to meet the specific needs identified in varying regional contexts, companies can optimize their market strategies and gain a competitive advantage.

Additionally, regulatory compliance and patient safety must remain at the forefront of strategic operations. Investing in stringent quality control measures and comprehensive clinical trials not only reinforces trust among healthcare providers but also mitigates risks associated with adverse therapeutic effects. In an industry that is under intense scrutiny, adherence to high safety standards and transparent communication with regulatory bodies are critical to sustaining market confidence.

Finally, fostering market education is essential. By developing informative platforms and outreach programs, industry incumbents can better communicate the benefits and innovative nature of new therapeutic approaches, thereby driving adoption among physicians and healthcare practitioners. These educational initiatives should be supported by compelling data and clearly articulated best practices to ensure that advancements in treatments are effectively disseminated across the healthcare continuum.

Adopting these actionable recommendations will equip industry leaders with the insights and tools necessary to navigate the complexities of the pediatric pneumococcal therapeutics market, ensuring a proactive response to both current and future challenges.

Conclusion: Shaping the Future of Pediatric Therapeutics

The evolution of pediatric pneumococcal therapeutics represents a transformative journey marked by innovative breakthroughs, strategic realignments, and a relentless pursuit of improved clinical outcomes. Analysis of the therapeutic landscape has underlined a dynamic interplay between groundbreaking drug developments and the sophisticated evolution of vaccine technologies. This confluence of advanced research, enhanced digital infrastructure, and strategic market segmentation has set the stage for a comprehensive rethinking of pediatric healthcare solutions.

The discussion provided an expansive view of the key areas shaping the market: from the detailed segmentation that distinguishes treatment modalities, age-specific considerations, and disease profiles, to the regional insights that reveal distinctive growth opportunities across the Americas, Europe including the Middle East and Africa, and the Asia-Pacific region. Moreover, competition among leading companies-ranging from established giants to innovative disruptors-illustrates the robust activity and potential for sustained momentum in the market.

In light of these factors, stakeholders can draw significant learnings regarding both the challenges and opportunities that are intrinsic to the field. The insights offered in this analysis support a strategic recalibration that emphasizes personalized medicine, the synergy of cross-sector partnerships, and a dedicated focus on regional diversity in healthcare needs. As the industry continues to evolve, the drive towards innovative, patient-centric solutions will remain a cornerstone of effective therapeutic strategies for pediatric populations worldwide.

Ultimately, the advancements in pediatric pneumococcal therapeutics provide not only a window into the future of treatment and prevention but also a roadmap for how industries can harmonize clinical innovations with market realities. This confluence of strategy and science underscores the promise of a healthier future for children, where precision medicine and proactive interventions stand as bulwarks against the challenges of infectious diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness about pneumococcal diseases among parents and healthcare providers
      • 5.1.1.2. Rising adoption of combination vaccines amplifies pediatric pneumococcal drugs
      • 5.1.1.3. Government initiatives and policies promoting vaccination and preventative healthcare
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D limit the entry of new competitors
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing age-specific formulations to better cater to different pediatric age groups
      • 5.1.3.2. Investing in telemedicine technology to expand reach and improve patient outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Meeting the growing ethical concerns and transparency demands regarding drug trials in children
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing adoption of conjugate vaccines due to their proven efficacy in infants
    • 5.2.2. Therapeutic Applications: Expanding the application of pediatrics pneumococcal therapeutics in invasive pneumococcal diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pediatrics Pneumococcal Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Drug
  • 6.3. Vaccine
    • 6.3.1. Conjugate Vaccine
    • 6.3.2. Polysaccharide Vaccine

7. Pediatrics Pneumococcal Therapeutics Market, by Age Group

  • 7.1. Introduction
  • 7.2. Infants
  • 7.3. Toddlers

8. Pediatrics Pneumococcal Therapeutics Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Bacterial Pneumonia
  • 8.3. Mycoplasma Pneumonia
  • 8.4. Viral Pneumonia

9. Pediatrics Pneumococcal Therapeutics Market, by Mode of Administration

  • 9.1. Introduction
  • 9.2. Intramuscular
  • 9.3. Intranasal
  • 9.4. Intravenous
  • 9.5. Oral

10. Pediatrics Pneumococcal Therapeutics Market, by Therapeutic Applications

  • 10.1. Introduction
  • 10.2. Invasive Pneumococcal Diseases
    • 10.2.1. Bacteremia
    • 10.2.2. Meningitis
  • 10.3. Non-Invasive Pneumococcal Diseases
    • 10.3.1. Otitis Media
    • 10.3.2. Sinusitis

11. Pediatrics Pneumococcal Therapeutics Market, by End-User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals

12. Americas Pediatrics Pneumococcal Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Pediatrics Pneumococcal Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Pediatrics Pneumococcal Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Sanofi and SK bioscience advance phase 3 PCV21 program to enhance global pediatric pneumococcal protection
    • 15.3.2. Hong Kong Department of Health approved Pfizer's 20-valent Pneumococcal Conjugate Vaccine
    • 15.3.3. Abbott India launched PneumoShield 14, a new pneumococcal conjugate vaccine
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Aurobindo Pharma Limited
  • 5. Baxter International Inc.
  • 6. Bharat Biotech International Limited
  • 7. Biocon Limited
  • 8. BioNTech SE
  • 9. CanSino Biologics Inc.
  • 10. CSL Limited
  • 11. Daiichi Sankyo Company, Limited
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. Eli Lilly and Company
  • 14. GlaxoSmithKline plc
  • 15. Glenmark Pharmaceuticals
  • 16. Hoffmann-La Roche AG
  • 17. Johnson & Johnson
  • 18. Lupin Limited
  • 19. Merck & Co., Inc.
  • 20. Moderna, Inc.
  • 21. Novartis AG
  • 22. Novavax, Inc.
  • 23. Panacea Biotec Ltd.
  • 24. Pfizer Inc.
  • 25. Sanofi S.A.
  • 26. Serum Institute of India Pvt. Ltd.
  • 27. Sinovac Biotech Ltd.
  • 28. Takeda Pharmaceutical Company Limited
  • 29. Teva Pharmaceutical Industries Ltd.
  • 30. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTERIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VIRAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTEREMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY SINUSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 222. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY